Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V350A and V350B EBV Vaccines in Healthy Participants
NCT06655324Phase 1Recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2024
- Primary completion
- Jul 2028
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Epstein-Barr virus infection comparing V350A, V350B and Placebo (3 arms). Primary endpoints: Number of Participants with Solicited Injection Site Adverse Events at 6 months, Number of Participants with Solicited Systemic Adverse Events at 6 months and 5 more. Started Dec 2024; status: recruiting.
02
Drugs
V350AV350B
03
Conditions
Epstein-Barr virus infection
Beyond the preview
Go deeper on NCT06655324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06655324.